Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/18/20
End: 05/31/26
Due: 05/31/27
Phase: N/A
Priority: Normal
Start: 02/14/20
End: 03/30/22
Due: 03/30/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM | NCT04176718 | Andrew Yee, MD | user2@example.com | None | 2020-05-18 | 2026-05-31 | 2027-05-31 | - | - | 2025-07-14 |
| Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | NCT04119336 | Andrew Yee, MD | user2@example.com | None | 2020-02-14 | 2022-03-30 | 2023-03-30 | - | - | 2025-07-14 |